Based on the findings, a noninferiority RCT study on survival of elderly patients with EGFR wild type advanced NSCLC between CHM and CT as well examining side effects as a secondary superiority endpoint is warranted. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.